German BioNTech and US Pfizer Announce 90% Effective Vaccine Candidate Against Covid-19

© iStockphoto

German company BioNTech and its US partner Pfizer announced on Monday that early results from ongoing Phase III trials showed that their vaccine was 90% effective in preventing COVID-19 infections.

The statement from the two companies is the first release of successful data from a large-scale trial of coronavirus vaccines. According to their reports, they found no serious safety concern connected with the vaccine. Researchers believe the immunizing effects will not be short-lived.

German Health Minister Jens Spahn said the European Union will wait to approve the vaccine until late-stage safety data is collected to ensure the broadest possible acceptance for the vaccine. “Most important for acceptance is that we make clear from the beginning that we will wait for clinical trials in Phase III before approval,” he said. Spahn welcomed the promising progress on a coronavirus vaccine, but added that the German government doesn’t want to make any hasty promises and bring something too quickly on the market. A possible coronavirus vaccine could be ready to go in the first three months of 2021, he said.


Read the full article at Deutsche Welle.